Singapore's Cordlife 9-month revenue falls amid suspension of new cord blood collections

By Reuters News


Overview

  • Singapore cord blood bank's 9M revenue fell 14.3% on absence of new collections

  • Net loss for 9M narrowed by 18.2% to S$5.8 mln due to cost controls

  • Gross profit margin improved to 58.1% from 57.8% last year


Outlook

  • Cordlife says priority is meeting regulatory requirements in Singapore

  • Company expects long-term demand for cord blood banking to remain supported by preventive healthcare trends


Result Drivers

  • SUSPENSION OF NEW COLLECTIONS - Revenue fell due to continued absence of new cord blood collections in Singapore

  • COST DISCIPLINE - Net loss narrowed as a result of lower operating expenses and ongoing cost optimisation efforts

  • EXPENSE REDUCTIONS - Selling, marketing and administrative expenses fell following the suspension of new collections


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

S$25.2 mln

9M Net Loss

S$5.8 mln

9M Gross Margin

58.1%

9M Gross Profit

S$14.6 mln


Reuters Recommended Reads

  • Nov 10 - New Zealand's Radius Residential Care HY profit jumps on higher occupancy

  • Nov 10 - New Zealand's Promisia Healthcare HY profit swings positive; raises 2027 outlook

  • Nov 11 - Singapore Airlines half-year revenue rises, but profit weighed down by fuel costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.